The fluoropyrimidines 5-fluorouracil (5FU) and capecitabine are the backbone of systemic therapy for metastatic colorectal cancer (mCRC). Side effects include hand-foot syndrome (HFS) and cardiovascular toxicity (CVT), which may necessitate dose reductions or discontinuation of treatment.
S-1 (Teysuno®) is an oral fluoropyrimidine that is licensed for use after fluoropyrimidine-induced HFS or CVT as it showed a lower incidence of those toxicities. It can be used as monotherapy or in combination with oxaliplatin or irinotecan.
ESMO Open published a clinical update in Oncology on 17 Mar 2026.
The item focuses on Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer.
Review the original article for the full source wording and details.